Approximately 72% of adults in the United States are classified as either overweight or obese based on body mass index

Overview Debates Related claims Topics

GLP-1 receptor agonist medications suppress appetite by targeting neural signaling pathways that regulate hunger and body weight settling points

Rural farming populations in northern Rwanda consuming high-carbohydrate diets display virtually no cases of obesity

In the United States, approximately 42% of adults are classified as obese

Approximately 50% to 60% of patients prescribed GLP-1 receptor agonist medications discontinue treatment within a few years

Over 1,000 distinct genetic loci have been associated with obesity risk in human genome-wide association studies

Rapid weight loss from GLP-1 receptor agonists often includes substantial reductions in skeletal muscle mass alongside fat loss

Populations in northern Rwanda experience sharp increases in obesity and type 2 diabetes following migration into urban environments

Adult obesity rates in the United States quadrupled between the mid-twentieth century and the 2020s

Heritability studies estimate that genetic variation explains between 30% and 70% of population-level body weight variation

Known obesity-associated genetic variants collectively account for between 6% and 17% of total variance in body weight

Forty-five percent of United States adolescents are classified as overweight or obese

Sam Tallent lost 120 pounds after quitting alcohol consumption and using the prescription medication Mounjaro

Excess body weight and obesity represent major modifiable risk factors for obstructive sleep apnea

Meaningful weight reduction reduces the apnea-hypopnea index in individuals whose obstructive sleep apnea is driven by excess adiposity

Participants taking Calocurb in a six-month clinical trial lost approximately 10 pounds of body fat and gained two pounds of muscle

In a nine-month study where Calocurb was stopped at six months, participants maintained their weight loss without rebound weight regain during a 12-week post-treatment period

In a six-month clinical trial of 150 participants with BMIs between 25 and 35, participants taking Calocurb lost an average of 5.5% of body weight

In a six-month clinical trial, participants receiving Calocurb experienced three and a half times more visceral fat loss compared to placebo

Approximately 90% of individuals who stop taking injectable GLP-1 receptor agonists regain their lost weight within 15 months

Restricting caloric intake by 25% on an ongoing basis causes ghrelin-mediated hunger to double over a four-month period